Vaccination Against SARS-CoV-2 Decreases Risk of Adverse Events in Patients who Develop COVID-19 Following Cancer Surgery

• Type of Material: Article
• Authors: Nathaniel B. Verhagen, Medical College of Wisconsin; Nicolas K. Koerber, Medical College of Wisconsin; Aniko Szabo, Medical College of Wisconsin; Bradley Taylor, Medical College of Wisconsin; J. Njeri Wainaina, Medical College of Wisconsin; Douglas B. Evans, Medical College of Wisconsin; Anai N. Kothari, Medical College of Wisconsin; Gregory Martin, Emory University; Rishikesan Kamaleswaran, Emory University; Richard Moffitt, Emory University
• Language: English
• Date: 2023-03-01
• Publisher: Springer Link
• Publication Version: Final Published Version
• Copyright Statement: This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022
• Final Published Version (URL): http://dx.doi.org/10.1245/s10434-022-12916-z
• Title of Journal or Parent Work: Annals of Surgical Oncology
• Volume: 30
• Issue: 3
• Start Page: 1305
• End Page: 1308
• Keywords: Vaccination; Neoplasms; Patients; SARS-CoV-2; Humans; COVID-19
• Research Categories: Health Sciences, Immunology; Health Sciences, Public Health; Biology, Virology

Abstract

Early in the COVID-19 pandemic, mortality rates were observed to exceed 25% in patients who developed postoperative SARS-CoV-2 infections.1 This prompted numerous perioperative structural and process changes to mitigate this risk.2,3 As the pandemic has progressed, the emergence of novel therapeutic and preventative measures have proven effective in decreasing the overall burden of SARS-CoV-2 infection. These advances likely reduce the risk in surgical patients; however, this has not been reexamined at a population level. This study reports 30-day adverse postoperative event rates in patients who develop postoperative COVID-19 and measures the impact of vaccination on these outcomes.